Your browser doesn't support javascript.
loading
Inferior Frontal Sulcal Hyperintensities on Brain MRI Are Associated with Amyloid Positivity beyond Age-Results from the Multicentre Observational DELCODE Study.
Dörner, Marc; Seebach, Katharina; Heneka, Michael T; Menze, Inga; von Känel, Roland; Euler, Sebastian; Schreiber, Frank; Arndt, Philipp; Neumann, Katja; Hildebrand, Annkatrin; John, Anna-Charlotte; Tyndall, Anthony; Kirchebner, Johannes; Tacik, Pawel; Jansen, Robin; Grimm, Alexander; Henneicke, Solveig; Perosa, Valentina; Meuth, Sven G; Peters, Oliver; Hellmann-Regen, Julian; Preis, Lukas; Priller, Josef; Spruth, Eike Jakob; Schneider, Anja; Fliessbach, Klaus; Wiltfang, Jens; Jessen, Frank; Rostamzadeh, Ayda; Glanz, Wenzel; Schulze, Jan Ben; Schiebler, Sarah Lavinia Florence; Buerger, Katharina; Janowitz, Daniel; Perneczky, Robert; Rauchmann, Boris-Stephan; Teipel, Stefan; Kilimann, Ingo; Laske, Christoph; Munk, Matthias H; Spottke, Annika; Roy-Kluth, Nina; Wagner, Michael; Frommann, Ingo; Lüsebrink, Falk; Dechent, Peter; Hetzer, Stefan; Scheffler, Klaus; Kleineidam, Luca; Stark, Melina.
Afiliação
  • Dörner M; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 39120 Magdeburg, Germany.
  • Seebach K; Department of Consultation-Liaison-Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
  • Heneka MT; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 39120 Magdeburg, Germany.
  • Menze I; Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 4367 Belvaux, Luxembourg.
  • von Känel R; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 39120 Magdeburg, Germany.
  • Euler S; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University, 39120 Magdeburg, Germany.
  • Schreiber F; Department of Consultation-Liaison-Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
  • Arndt P; Department of Consultation-Liaison-Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
  • Neumann K; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 39120 Magdeburg, Germany.
  • Hildebrand A; Department of Neurology, Otto-von-Guericke University, 39120 Magdeburg, Germany.
  • John AC; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 39120 Magdeburg, Germany.
  • Tyndall A; Department of Neurology, Otto-von-Guericke University, 39120 Magdeburg, Germany.
  • Kirchebner J; Department of Neurology, Otto-von-Guericke University, 39120 Magdeburg, Germany.
  • Tacik P; Department of Neurology, Otto-von-Guericke University, 39120 Magdeburg, Germany.
  • Jansen R; Department of Neurology, Otto-von-Guericke University, 39120 Magdeburg, Germany.
  • Grimm A; Department of Neuroradiology, Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
  • Henneicke S; Department of Forensic Psychiatry, University Hospital of Psychiatry Zurich, University of Zurich, 8032 Zurich, Switzerland.
  • Perosa V; Department of Parkinson's Disease, Sleep and Movement Disorders, University Hospital Bonn, 53127 Bonn, Germany.
  • Meuth SG; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 53127 Bonn, Germany.
  • Peters O; Department of Neurology, Heinrich Heine University, 40225 Düsseldorf, Germany.
  • Hellmann-Regen J; Center for Neurology, Tuebingen University Hospital and Hertie-Institute for Clinical Brain Research, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany.
  • Preis L; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 39120 Magdeburg, Germany.
  • Priller J; Department of Neurology, Otto-von-Guericke University, 39120 Magdeburg, Germany.
  • Spruth EJ; J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Schneider A; Department of Neurology, Heinrich Heine University, 40225 Düsseldorf, Germany.
  • Fliessbach K; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 10117 Berlin, Germany.
  • Wiltfang J; Institute of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 14129 Berlin, Germany.
  • Jessen F; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 10117 Berlin, Germany.
  • Rostamzadeh A; Department of Psychiatry and Neurosciences, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
  • Glanz W; German Center for Mental Health (DZPG), Partner Site Berlin, 10785 Berlin, Germany.
  • Schulze JB; Institute of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 14129 Berlin, Germany.
  • Schiebler SLF; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 10117 Berlin, Germany.
  • Buerger K; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Janowitz D; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University Munich, 81675 Munich, Germany.
  • Perneczky R; UK Dementia Research Institute (UK DRI), University of Edinburgh, Edinburgh EH16 4SB, UK.
  • Rauchmann BS; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 10117 Berlin, Germany.
  • Teipel S; Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Kilimann I; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 53127 Bonn, Germany.
  • Laske C; Department of Cognitive Disorders and Old Age Psychiatry, University Hospital Bonn, 53127 Bonn, Germany.
  • Munk MH; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 53127 Bonn, Germany.
  • Spottke A; Department of Cognitive Disorders and Old Age Psychiatry, University Hospital Bonn, 53127 Bonn, Germany.
  • Roy-Kluth N; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 37075 Goettingen, Germany.
  • Wagner M; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, 37075 Goettingen, Germany.
  • Frommann I; Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal.
  • Lüsebrink F; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 53127 Bonn, Germany.
  • Dechent P; Department of Psychiatry, Medical Faculty, University of Cologne, 50924 Cologne, Germany.
  • Hetzer S; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany.
  • Scheffler K; Department of Psychiatry, Medical Faculty, University of Cologne, 50924 Cologne, Germany.
  • Kleineidam L; German Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, 39120 Magdeburg, Germany.
  • Stark M; Department of Consultation-Liaison-Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Diagnostics (Basel) ; 14(9)2024 Apr 30.
Article em En | MEDLINE | ID: mdl-38732354
ABSTRACT
Inferior frontal sulcal hyperintensities (IFSHs) on fluid-attenuated inversion recovery (FLAIR) sequences have been proposed to be indicative of glymphatic dysfunction. Replication studies in large and diverse samples are nonetheless needed to confirm them as an imaging biomarker. We investigated whether IFSHs were tied to Alzheimer's disease (AD) pathology and cognitive performance. We used data from 361 participants along the AD continuum, who were enrolled in the multicentre DELCODE study. The IFSHs were rated visually based on FLAIR magnetic resonance imaging. We performed ordinal regression to examine the relationship between the IFSHs and cerebrospinal fluid-derived amyloid positivity and tau positivity (Aß42/40 ratio ≤ 0.08; pTau181 ≥ 73.65 pg/mL) and linear regression to examine the relationship between cognitive performance (i.e., Mini-Mental State Examination and global cognitive and domain-specific performance) and the IFSHs. We controlled the models for age, sex, years of education, and history of hypertension. The IFSH scores were higher in those participants with amyloid positivity (OR 1.95, 95% CI 1.05-3.59) but not tau positivity (OR 1.12, 95% CI 0.57-2.18). The IFSH scores were higher in older participants (OR 1.05, 95% CI 1.00-1.10) and lower in males compared to females (OR 0.44, 95% CI 0.26-0.76). We did not find sufficient evidence linking the IFSH scores with cognitive performance after correcting for demographics and AD biomarker positivity. IFSHs may reflect the aberrant accumulation of amyloid ß beyond age.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article